Peptides Publishing Nootropic Peptides: Evidence-Weighted Practical Guide
Structured in layers so readers can get quick clarity first, then drill into trial-level detail. Switch reading modes to match your depth preference.
Reading mode
Research Report
Nootropic Peptides: Evidence-Weighted Practical Guide
This report is structured in layers so readers can get quick clarity first, then drill into trial-level detail. Across reviewed candidates, none currently clears the bar for a broadly recommended, low-risk, legally straightforward cognitive enhancer in major Western jurisdictions.
Strongest human evidence density
Cerebrolysin
Most RCT volume in clinical populations, but synthesis evidence remains mixed and cautionary for broad claims.
Biggest confidence penalty
Dihexa
No robust human cognition trials in this set and integrity concerns around a foundational paper materially lower confidence.
Common pattern across category
Promise exceeds proof
Mechanistic plausibility is common, but modern replicated human outcomes and legal/quality certainty are limited.
Find By Use Case
Use this first-pass framing before opening individual dossiers. It keeps expectations realistic and separates exploratory signals from clinically anchored evidence.
Healthy performance enhancement
Weak evidence for reliable benefitHuman trials are sparse for healthy users. Risk-benefit is generally unfavorable when legal and quality uncertainty are included.
Post-stroke or cognitive impairment contexts
Most clinical data exists hereCerebrolysin and Cortexin have the deepest clinical literature, but outcomes are mixed and must be interpreted with indication-specific caution.
Anxiety-related cognitive interference
Indirect pathwaySelank's better-supported signal is anxiolysis, with cognition potentially improving secondarily rather than from direct nootropic effect.
Ranked Comparison
Scores are on a 0–5 scale: clinical effectiveness 30%, evidence strength 30%, safety 20%, availability/cost 15%, anecdotal quality 5%.
9 all candidates · avg overall 1.6/5
| Candidate | Overall | Clinical | Evidence | Safety | Availability |
|---|---|---|---|---|---|
| Cerebrolysin | 2.6 | 2.5 | 3.0 | 2.5 | 2.0 |
| Noopept | 2.4 | 2.0 | 2.5 | 2.5 | 2.5 |
| Cortexin | 1.9 | 2.0 | 2.0 | 2.0 | 1.5 |
| Semax | 1.9 | 2.0 | 2.0 | 2.0 | 1.5 |
| Selank | 1.8 | 1.5 | 2.0 | 2.0 | 1.5 |
| P021 / P21 | 1.3 | 0.5 | 2.0 | 2.0 | 1.0 |
| EDR / Pinealon | 1.2 | 0.5 | 1.5 | 2.0 | 1.0 |
| Dihexa | 0.8 | 0.0 | 1.0 | 1.0 | 1.0 |
| N-Acetyl Semax | 0.8 | 0.0 | 1.0 | 1.5 | 1.0 |
Peptide Dossiers
Each dossier keeps the same structure: practical signal, what limits confidence, and direct links to the strongest supporting sources.